A novel FGF2 antagonist peptide P8 with potent antiproliferation activity

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Fibroblast growth factors (FGFs) are implicated in cancer development and progression.
• FGF2 is overexpressed in certain tumors, making it a potential therapeutic target.
• Targeting FGF2 can inhibit tumor cell growth, highlighting its therapeutic relevance.

Purpose of the Study:

• To identify and characterize a novel peptide antagonist for FGF2.
• To evaluate the anti-tumor effects of the identified peptide.
• To investigate the molecular mechanisms underlying the peptide's action.

Main Methods:

• Phage display technology was employed to discover FGF2-binding peptides.
• Alanine scanning was used for peptide optimization.
• Cell proliferation assays, cell cycle analysis, and Western blotting were performed to assess peptide efficacy and mechanism.

Main Results:

• A novel FGF2-binding peptide (P8) was identified.
• P8 suppressed FGF2-induced proliferation without cytotoxicity and induced G0/G1 cell cycle arrest.
• P8 downregulated the fibroblast growth factor receptor substrate 2α (FRS2α)/ERK signaling cascade and inhibited FRS2α phosphorylation.

Conclusions:

• The P8 peptide demonstrates significant anti-tumor activity by inhibiting FGF2 signaling.
• P8 acts as a multi-target antagonist, affecting key pathways in cancer cells.
• P8 holds promise as a potential therapeutic agent for cancer treatment.